Welcome to our dedicated page for CALCIMEDICA SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like reviewing lab notebooks. CalciMedica’s 10-K spans pages of CRAC-channel biology, trial endpoints and burn-rate math that most investors simply don’t have time to decode. If you have ever wondered, “CalciMedica SEC filings explained simply,” this page was built to end the struggle.
Stock Titan’s AI distills every document the moment it hits EDGAR. Our platform delivers real-time updates on CalciMedica Form 4 insider transactions, surfaces R&D expense trends from each CalciMedica quarterly earnings report 10-Q filing, and flags pivotal study results buried in an 8-K. The same engine powers plain-English answers to questions investors routinely ask: How did cash runway shift this quarter? Which executives exercised options? What milestones were added to the risk-factor section?
Here’s what you can track today:
- CalciMedica annual report 10-K simplified—AI pulls pipeline timelines and liquidity tables in seconds.
- CalciMedica 8-K material events explained—immediate alerts on trial read-outs or financing news.
- CalciMedica executive stock transactions Form 4 with pattern recognition for insider buying.
- CalciMedica proxy statement executive compensation—see how pay aligns with clinical progress.
- CalciMedica earnings report filing analysis—compare quarter-over-quarter R&D spend effortlessly.
Whether you are understanding CalciMedica SEC documents with AI for the first time or fine-tuning a valuation model, our coverage of CalciMedica insider trading Form 4 transactions and every other filing type gives you the clarity you need—no scientific PhD required.
Eric W. Roberts, Chief Business Officer, Director, and 10% Owner of CalciMedica (CALC), reported significant insider trading activity on June 26, 2025. Roberts purchased 4,500 shares of common stock at a weighted average price of $1.4406 per share through his Roth IRA account.
Following this transaction, Roberts' total beneficial ownership includes:
- 164,706 shares held directly
- 832,704 shares held indirectly through various entities including:
- Multiple Roth IRA accounts totaling 93,378 shares
- Valence Investments SPV entities holding 739,326 shares across three vehicles
The transaction demonstrates continued insider confidence in CalciMedica, with Roberts maintaining substantial holdings both directly and through investment vehicles. The purchase price range was between $1.43 and $1.4499 per share.
CalciMedica (symbol: CALC) has filed a Post-Effective Amendment No. 1 to its Form S-8 Registration Statement (No. 333-288287) on June 27, 2025. The amendment's sole purpose is to include Exhibit 23.3 - the Consent of Ernst & Young LLP as Independent Registered Public Accounting Firm - which was inadvertently omitted in the original filing.
The filing relates to the company's 2023 Equity Incentive Plan and 2023 Employee Stock Purchase Plan. CalciMedica is identified as a:
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
The company is led by A. Rachel Leheny, Ph.D. as CEO and Principal Executive Officer, with Stephen Bardin serving as CFO. The board is chaired by Robert N. Wilson. The company is headquartered in La Jolla, California, and operates under Delaware jurisdiction.
CalciMedica (NASDAQ: CALC) filed an 8-K summarizing the 2025 Annual Meeting held on 24 Jun 2025.
- Equity Incentive Plan amended: share reserve increased by 600,000 shares (≈4.3 % of the 13.97 M shares outstanding).
- Three Class II directors—Rachel Leheny, Eric Roberts, Frederic Guerard—re-elected for terms ending 2028.
- Baker Tilly US ratified as independent auditor for FY 2025.
The amendment enhances retention tools but introduces incremental dilution; no additional financial data or strategic shifts were disclosed.
CalciMedica Chief Medical Officer Sudarshan Hebbar received a stock option grant for 83,300 shares of common stock on June 24, 2025. The options were granted with an exercise price of $1.53 per share and are immediately exercisable with an expiration date of April 22, 2035.
Key details of the transaction:
- The option grant was initially approved by the Board on April 23, 2025, contingent on stockholder approval
- Stockholders approved the amended 2023 Equity Incentive Plan on June 24, 2025, finalizing the grant
- Options represent direct ownership and were granted under the company's Amended 2023 Equity Incentive Plan
- The filing was signed by John Dunn as attorney-in-fact on June 26, 2025
CalciMedica, Inc. (CALC) – Form 4 insider transaction by CFO Stephen Bardin
On 26 June 2025, Chief Financial Officer Stephen Bardin executed two reportable transactions:
- Open-market purchase: 2,000 shares of CALC common stock at a weighted-average price of $1.5025 (price range $1.45-$1.54). The shares are held indirectly by The Bardin Family Trust dated 4 June 2024.
- Employee stock option grant: 20,000 options with an exercise price of $1.53 per share, immediately exercisable and expiring 22 April 2035. The grant was approved by the Board on 23 April 2025 and became effective upon shareholder approval of the amended 2023 Equity Incentive Plan on 24 June 2025.
Post-transaction ownership
- Indirect: 3,000 shares (Bardin Family Trust)
- Direct: 40,000 shares
- Derivative: 20,000 stock options
The filing also corrects a prior Form 4 (3 June 2025) that had misclassified 1,000 trust-held shares as directly owned. No other financial metrics or operational updates were included.
CalciMedica Chief Scientific Officer Kenneth A. Stauderman received a stock option grant for 47,125 shares of common stock on June 24, 2025. The option has an exercise price of $1.53 per share and expires on April 22, 2035.
Key details of the transaction:
- The option grant was initially approved by the Board on April 23, 2025, contingent on stockholder approval
- Stockholders approved the amended 2023 Equity Incentive Plan on June 24, 2025, finalizing the grant
- Options are immediately exercisable upon grant
- This represents a new derivative securities position for the executive
This Form 4 filing indicates ongoing executive compensation alignment through equity incentives, with the exercise price suggesting the company's current market valuation and growth expectations.
Eric W. Roberts, Chief Business Officer, Director, and 10% Owner of CalciMedica, reported receiving a stock option grant for 72,750 shares of common stock. The option grant was initially approved by the Board on April 23, 2025, contingent on stockholder approval of amendments to the company's 2023 Equity Incentive Plan.
Key details of the stock option:
- Exercise price: $1.53 per share
- Grant date: June 24, 2025 (following stockholder approval)
- Expiration date: April 22, 2035
- Immediately exercisable upon grant
- Direct ownership form
The transaction was reported via Form 4 filing, with the document signed by John Dunn as attorney-in-fact on June 26, 2025. This equity compensation grant aligns the executive's interests with those of shareholders through long-term stock ownership potential.
CalciMedica, Inc. (CALC) – Form 4 insider filing
On 24 June 2025, President & COO Michael J. Dunn was granted 47,125 employee stock options with an exercise price of $1.53 per share. The award becomes immediately exercisable and will expire on 22 April 2035.
The option grant had been approved by the Board on 23 April 2025 subject to stockholder approval of amendments to the company’s 2023 Equity Incentive Plan; shareholders ratified the amendment on the same date as the grant (24 June 2025). Following the transaction, Mr. Dunn now beneficially owns 47,125 derivative securities (stock options) directly.
No open-market purchases or sales of common shares were reported, so the filing represents incentive-based compensation rather than a change in Mr. Dunn’s outright share ownership.
Rachel Leheny, Chief Executive Officer, Director, and 10% Owner of CalciMedica (CALC), received a stock option grant for 77,625 shares of common stock on June 24, 2025. The options were granted with the following key terms:
- Exercise price set at $1.53 per share
- Options are immediately exercisable
- Expiration date of April 22, 2035
- Granted under the amended 2023 Equity Incentive Plan
The grant was initially approved by the Board on April 23, 2025, but was contingent on stockholder approval of amendments to the 2023 Equity Incentive Plan, which was obtained on June 24, 2025. This Form 4 filing represents a direct ownership position for Leheny, who serves in multiple leadership roles at the company.
CalciMedica Director Frederic Guerard received multiple stock option grants on June 24, 2025, following stockholder approval of the Amended 2023 Equity Incentive Plan. The grants include:
- 10,000 options at $1.53/share, vesting monthly over one year from March 26, 2025
- 5,000 immediately exercisable options at $1.53/share
- 15,000 options at $1.53/share, vesting monthly over one year from April 1, 2025
- 10,000 options at $1.65/share, vesting monthly over one year from June 24, 2025
All options expire in 2035, with the first three expiring on April 22 and the last on June 23. The final grant will fully vest by the 2026 annual stockholder meeting. Total grant value represents potential rights to purchase 40,000 shares of common stock. These grants were initially approved by the Board on April 23, 2025, contingent on stockholder approval.
FAQ
What is the current stock price of CALCIMEDICA (CALC)?
What is the market cap of CALCIMEDICA (CALC)?
What is the primary focus of CalciMedica Inc?
Which therapeutic areas are targeted by CalciMedica's pipeline?
How does CalciMedica's technology work?
What distinguishes Auxora™ from other drug candidates?
Why is CRAC channel inhibition important in treating inflammatory diseases?
What type of clinical trials is CalciMedica conducting?
How is CalciMedica positioned within its competitive landscape?
